Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

8.610 -0.180 (-2.05%)
Streaming Delayed Price Updated: 9:49 AM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Certara, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
From Certara
Via GlobeNewswire
News headline image
Healthcare AI Exits Pilot Phase, Enters Production Deployment
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Certara Appoints Jon Resnick as Chief Executive Officer
From Certara
Via GlobeNewswire
News headline image
Certara Reports Third Quarter 2025 Financial Results
Updates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Automates Scientific Workflows with Phoenix® Cloud
New cloud capabilities cut time to create Tables, Figures, and Listings by 50% 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Expands Biosimulation Market with AI-Driven QSP Platform
Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies 
From Certara
Via GlobeNewswire
News headline image
Certara Scientists are Among the Topmost Cited Biopharma Researchers
Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
From Certara
Via GlobeNewswire
News headline image
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurements 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Reports Second Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
From Certara
Via GlobeNewswire
News headline image
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
From Certara
Via GlobeNewswire
News headline image
Certara Announces Expansion of Clinical Technology Collaboration with Merck
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality 
From Certara
Via GlobeNewswire
News headline image
Certara Reports First Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies 
From Certara
Via GlobeNewswire
News headline image
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization
From Certara
Via GlobeNewswire
News headline image
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-making 
From Certara
Via GlobeNewswire
News headline image
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
McKemey joins Certara to accelerate growth of its strategic drug development solutions 
From Certara
Via GlobeNewswire
News headline image
Certara Reports Fourth Quarter 2024 Financial Results
Issues Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Certara
Via GlobeNewswire
News headline image
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list 
From Certara
Via GlobeNewswire
News headline image
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
News headline image
Certara Appoints John Reynders as New Independent Board Member
From Certara
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.